Phio Pharmaceuticals Corp. Revenue | PHIO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Phio Pharmaceuticals Corp.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
-	-	-	-	-	4.36 K	21 K	138 K	15 K	19 K	34 K	71 K	399 K	97 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
399 K	4.36 K	88.7 K

Quarterly Revenue Phio Pharmaceuticals Corp.

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21 K	-	57 K	58 K	23 K	-	-	-	-	-	19 K	9 K	10 K	-	34 K	34 K	34 K	-	-	-	29 K	-	92 K	225 K	53 K	-	57 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
225 K	9 K	50.3 K

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	372 M	-	-	-	Russia
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	223 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	3 M	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	11.6 M	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	190 M	$ 101.8	0.08 %	$ 6.62 B	USA
Seer SEER	16.6 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	9.68 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	94.6 M	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	172 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	119 K	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	4.91 M	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	443 M	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	184 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	102 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	1 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	719 M	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	257 K	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	1.14 M	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	4.58 T	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	1.22 B	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	49.3 K	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	1.5 B	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	616 M	$ 55.74	0.58 %	$ 8.04 B	USA
Taysha Gene Therapies TSHA	9.77 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	19.4 M	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	110 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	3.18 B	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	66.8 M	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	33.2 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	82 M	-	-	$ 98.4 M	USA
NextCure NXTC	22.4 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	35.6 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	70.8 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	785 K	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	12 B	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	30.9 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	1.02 M	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	40.4 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	42.7 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	13.1 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	2.98 M	$ 4.28	0.86 %	$ 7.28 M	USA
XBiotech XBIT	4.01 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	500 K	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	7.5 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	292 M	$ 8.48	0.12 %	$ 1.36 B	USA